COVAXX Gets Supply Deals Worth US$2.8 Billion for Potential Covid-19 Vaccine
RIO DE JANEIRO, BRAZIL – COVAXX, a unit of United Biomedical Inc, said on Thursday it has received purchase commitments totaling US$2.8 billion to deliver more than 140 million doses of its potential Covid-19 vaccine to developing countries, including Brazil, Peru and Ecuador.
The multitope peptide-based vaccine is currently in early-stage trials in Taiwan, lagging some of the frontrunners in the race to develop a safe and effective vaccine.
The U.S.-based company signed an agreement in September with Brazilian laboratory and hospital group DASA S.A. to conduct mid-to-late stage trials for the vaccine in Brazil.
COVAXX estimates it can produce 100 million doses in first half of next year and 1 billion by the end of 2021.
Last month, the company signed a logistics partnership with Maersk for transportation and supply chain services that will be needed to deliver the vaccine around the world.
More: Brazil news in English, every day from The Rio Times.
This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error · Editorial responsibility: Matthias Camenzind, Editor-in-Chief